









市场行情
/
股票
/
nasdaq-alec
/

Alector Inc

ALEC

1.465USD

+0.065+4.64%

交易中（美东）报价延迟15分钟

157.41M总市值

亏损市盈率 TTM



Alector Inc

1.465

+0.065+4.64%

概览公司财务分析

概览

公司

财务

分析

关于 Alector Inc 公司

Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Alector Inc简介



公司代码ALEC

公司名称Alector Inc

上市日期Feb 07, 2019

CEORosenthal (Arnon)

员工数量238

证券类型Ordinary Share

年结日Feb 07

公司地址131 Oyster Point Blvd., Suite 600

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话14152315660

网址https://alector.com

公司代码ALEC

上市日期Feb 07, 2019

CEORosenthal (Arnon)

Alector Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Arnon Rosenthal, Ph.D.

Chief Executive Officer, Co-Founder, Director

5.60M

-1.83%

Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.

President, Head - Research and Development

90.76K

-31.47%

Dr. Kristine Yaffe

Independent Director

60.41K

+84.69%

Dr. Richard H. Scheller, Ph.D.

Director

56.41K

+103.58%

Dr. Paula Hammond, Ph.D.

Independent Director

39.91K

-25.97%

Mr. Mark Altmeyer

Independent Director

39.01K

+278.29%

Mr. Giacomo Salvadore, M.D.

Chief Medical Officer

Mr. Louis J. (Lou) Lavigne, Jr.

Independent Chairman of the Board

Dr. Errol De Souza, Ph.D.

Independent Director

Dr. Elizabeth A. (Betsy) Garofalo, M.D.

Independent Director

名称

名称/职务

职务

持股

持股变动

Dr. Arnon Rosenthal, Ph.D.

Chief Executive Officer, Co-Founder, Director

5.60M

-1.83%

Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.

President, Head - Research and Development

90.76K

-31.47%

Dr. Kristine Yaffe

Independent Director

60.41K

+84.69%

Dr. Richard H. Scheller, Ph.D.

Director

56.41K

+103.58%

Dr. Paula Hammond, Ph.D.

Independent Director

39.91K

-25.97%

Mr. Mark Altmeyer

Independent Director

39.01K

+278.29%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

Fidelity Management & Research Company LLC

13.91%

TCG Crossover Management, LLC

9.16%

RTW Investments L.P.

6.40%

Polaris Venture Partners

6.28%

The Vanguard Group, Inc.

5.53%

其他

58.72%

持股股东

占比

Fidelity Management & Research Company LLC

13.91%

TCG Crossover Management, LLC

9.16%

RTW Investments L.P.

6.40%

Polaris Venture Partners

6.28%

The Vanguard Group, Inc.

5.53%

其他

58.72%

股东类型

持股股东

占比

Investment Advisor

42.89%

Investment Advisor/Hedge Fund

20.25%

Hedge Fund

9.06%

Venture Capital

7.75%

Individual Investor

6.69%

Corporation

3.25%

Research Firm

2.15%

Pension Fund

0.24%

Bank and Trust

0.09%

其他

7.63%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

349

90.03M

98.61%

+10.00M

2025Q3

362

80.15M

106.47%

+1.69M

2025Q2

360

78.42M

102.48%

-2.24M

2025Q1

365

81.31M

103.38%

-22.06M

2024Q4

366

82.35M

103.74%

-11.52M

2024Q3

362

84.26M

96.78%

-1.24M

2024Q2

361

85.77M

94.54%

-889.02K

2024Q1

362

88.56M

87.42%

+4.86M

2023Q4

367

76.77M

98.07%

+993.74K

2023Q3

372

75.68M

93.10%

+3.65M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Fidelity Management & Research Company LLC

15.00M

14.82%

+608.65K

+4.23%

Jun 30, 2025

Polaris Venture Partners

9.85M

9.74%

Sep 30, 2024

The Vanguard Group, Inc.

5.99M

5.92%

-65.34K

-1.08%

Jun 30, 2025

Rosenthal (Arnon)

5.53M

5.46%

-51.56K

-0.92%

Sep 02, 2025

BlackRock Institutional Trust Company, N.A.

6.19M

6.11%

-228.85K

-3.57%

Jun 30, 2025

Merck & Co Inc

3.55M

3.5%

Jun 30, 2025

Acadian Asset Management LLC

2.17M

2.14%

+729.73K

+50.65%

Jun 30, 2025

T. Rowe Price Associates, Inc.

4.83M

4.77%

+4.19M

+652.19%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.34%

iShares Neuroscience and Healthcare ETF

0.17%

iShares Micro-Cap ETF

0.02%

ProShares Ultra Nasdaq Biotechnology

0.02%

Invesco Nasdaq Biotechnology ETF

0.01%

iShares Biotechnology ETF

0.01%

iShares Russell 2000 Value ETF

0.01%

iShares Russell 2000 ETF

Fidelity MSCI Health Care Index ETF

JPMorgan Fundamental Data Science Small Core ETF

Invesco NASDAQ Future Gen 200 ETF

占比0.34%

iShares Neuroscience and Healthcare ETF

占比0.17%

iShares Micro-Cap ETF

占比0.02%

ProShares Ultra Nasdaq Biotechnology

占比0.02%

Invesco Nasdaq Biotechnology ETF

占比0.01%

iShares Biotechnology ETF

占比0.01%

iShares Russell 2000 Value ETF

占比0.01%

iShares Russell 2000 ETF

占比0%

Fidelity MSCI Health Care Index ETF

占比0%

JPMorgan Fundamental Data Science Small Core ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Alector Inc的前五大股东是谁？



Alector Inc 的前五大股东如下：
Fidelity Management & Research Company LLC持有股份：15.00M，占总股份比例：14.82%。
Polaris Venture Partners持有股份：9.85M，占总股份比例：9.74%。
The Vanguard Group, Inc.持有股份：5.99M，占总股份比例：5.92%。
Rosenthal (Arnon)持有股份：5.53M，占总股份比例：5.46%。
BlackRock Institutional Trust Company, N.A.持有股份：6.19M，占总股份比例：6.11%。